We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Tasty crumbs

3 October 2011 By Robert Cyran

The $3.9 bln buyout of drug developer PPD is one of the year’s biggest. The by-the-book takeover provides a nice premium to shareholders and leveraged upside for buyers Carlyle and H&F. But the seemingly simple deal was a slog and is a reminder of how few there are to go around.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)